AIMS/HYPOTHESIS: The hormone glucagon-like peptide 1 (GLP-1) is released in response to a meal from the intestinal L-cells, where it is processed from proglucagon by the proconvertase (PC)1/3. In contrast, in the adult islets proglucagon is processed to glucagon by the PC2 enzyme. The aim of the study was to evaluate if, during the development of diabetes, alpha cells produce GLP-1 that, in turn, might trigger beta cell growth. METHODS: Beta cell mass, GLP-1 and insulin levels were measured in the gerbil Psammomys obesus (P. obesus), a rodent model of nutritionally induced diabetes. Furthermore, the presence of biologically active forms of GLP-1 and PC1/3 in alpha cells was demonstrated by immunofluorescence, and the release of GLP-1 from isolated P. obesus, mouse and human islets was investigated. RESULTS: During the development of diabetes in P. obesus, a significant increase in GLP-1 was detected in the portal vein (9.8 ± 1.5 vs 4.3 ± 0.7 pmol/l, p < 0.05), and in pancreas extracts (11.4 ± 2.2 vs 5.1 ± 1.3 pmol/g tissue, p < 0.05). Freshly isolated islets from hyperglycaemic animals released more GLP-1 following 24 h culture than islets from control animals (28.2 ± 4.4 pmol/l vs 5.8 ± 2.4, p < 0.01). GLP-1 release was increased from healthy P. obesus islets following culture in high glucose for 6 days (91 ± 9.1 pmol/l vs 28.8 ± 6.6, p < 0.01). High levels of GLP-1 were also found to be released from human islets. PC1/3 colocalised weakly with alpha cells. CONCLUSIONS/ INTERPRETATION: GLP-1 release from alpha cells is upregulated in P. obesus during the development of diabetes. A similar response is seen in islets exposed to high glucose, which supports the hypothesis that GLP-1 released from alpha cells promotes an increase in beta cell mass and function during metabolic challenge such as diabetes.
AIMS/HYPOTHESIS: The hormone glucagon-like peptide 1 (GLP-1) is released in response to a meal from the intestinal L-cells, where it is processed from proglucagon by the proconvertase (PC)1/3. In contrast, in the adult islets proglucagon is processed to glucagon by the PC2 enzyme. The aim of the study was to evaluate if, during the development of diabetes, alpha cells produce GLP-1 that, in turn, might trigger beta cell growth. METHODS: Beta cell mass, GLP-1 and insulin levels were measured in the gerbil Psammomys obesus (P. obesus), a rodent model of nutritionally induced diabetes. Furthermore, the presence of biologically active forms of GLP-1 and PC1/3 in alpha cells was demonstrated by immunofluorescence, and the release of GLP-1 from isolated P. obesus, mouse and human islets was investigated. RESULTS: During the development of diabetes in P. obesus, a significant increase in GLP-1 was detected in the portal vein (9.8 ± 1.5 vs 4.3 ± 0.7 pmol/l, p < 0.05), and in pancreas extracts (11.4 ± 2.2 vs 5.1 ± 1.3 pmol/g tissue, p < 0.05). Freshly isolated islets from hyperglycaemic animals released more GLP-1 following 24 h culture than islets from control animals (28.2 ± 4.4 pmol/l vs 5.8 ± 2.4, p < 0.01). GLP-1 release was increased from healthy P. obesus islets following culture in high glucose for 6 days (91 ± 9.1 pmol/l vs 28.8 ± 6.6, p < 0.01). High levels of GLP-1 were also found to be released from human islets. PC1/3 colocalised weakly with alpha cells. CONCLUSIONS/ INTERPRETATION:GLP-1 release from alpha cells is upregulated in P. obesus during the development of diabetes. A similar response is seen in islets exposed to high glucose, which supports the hypothesis that GLP-1 released from alpha cells promotes an increase in beta cell mass and function during metabolic challenge such as diabetes.
Authors: Y Nie; M Nakashima; P L Brubaker; Q L Li; R Perfetti; E Jansen; Y Zambre; D Pipeleers; T C Friedman Journal: J Clin Invest Date: 2000-04 Impact factor: 14.808
Authors: Bronwen Martin; Cedrick D Dotson; Yu-Kyong Shin; Sunggoan Ji; Daniel J Drucker; Stuart Maudsley; Steven D Munger Journal: Ann N Y Acad Sci Date: 2009-07 Impact factor: 5.691
Authors: Y Takeda; Y Fujita; J Honjo; T Yanagimachi; H Sakagami; Y Takiyama; Y Makino; A Abiko; T J Kieffer; M Haneda Journal: Diabetologia Date: 2011-11-10 Impact factor: 10.122
Authors: Lihua Ye; Morgan A Robertson; Daniel Hesselson; Didier Y R Stainier; Ryan M Anderson Journal: Development Date: 2015-04-15 Impact factor: 6.868
Authors: Jeremy A Lavine; Carly R Kibbe; Mieke Baan; Sirinart Sirinvaravong; Heidi M Umhoefer; Kimberly A Engler; Louise M Meske; Kaitlyn A Sacotte; Daniel P Erhardt; Dawn Belt Davis Journal: Am J Physiol Endocrinol Metab Date: 2015-09-22 Impact factor: 4.310
Authors: Helga Ellingsgaard; Irina Hauselmann; Beat Schuler; Abdella M Habib; Laurie L Baggio; Daniel T Meier; Elisabeth Eppler; Karim Bouzakri; Stephan Wueest; Yannick D Muller; Ann Maria Kruse Hansen; Manfred Reinecke; Daniel Konrad; Max Gassmann; Frank Reimann; Philippe A Halban; Jesper Gromada; Daniel J Drucker; Fiona M Gribble; Jan A Ehses; Marc Y Donath Journal: Nat Med Date: 2011-10-30 Impact factor: 53.440
Authors: P Marchetti; R Lupi; M Bugliani; C L Kirkpatrick; G Sebastiani; F A Grieco; S Del Guerra; V D'Aleo; S Piro; L Marselli; U Boggi; F Filipponi; L Tinti; L Salvini; C B Wollheim; F Purrello; F Dotta Journal: Diabetologia Date: 2012-09-11 Impact factor: 10.122